Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FQJU6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,737
Award facts
- Contract value 100% obligated
- $37,736.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $37,736.66 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, awarded on December 5, 2025, with an ultimate completion date of December 8, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. operates as a critical supplier within the Department of Defense pharmaceutical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, vaccines, and medical consumables to federal military healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy established on November 13, 2025. The PPV-G GEN V contract, designated as SPE2DR with a ceiling value of $499,999,999 and completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products to support the recurring medical supply needs of military healthcare facilities worldwide. As a single-award prime vendor contractor, DMS Pharmaceutical Group is positioned to serve as a key pharmaceutical supplier for Department of Defense healthcare operations globally through multiple 30-month performance periods.
Quick answers
Who was awarded contract SPE2DR26FQJU6?
SPE2DR26FQJU6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FQJU6 worth?
The government has obligated $37,737 on SPE2DR26FQJU6.
Is contract SPE2DR26FQJU6 an order under another contract?
Yes. SPE2DR26FQJU6 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJU6 competed?
The extent of competition for SPE2DR26FQJU6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award